SARS-CoV-2 infection and COVID-19 vaccination in pregnancy

Nature reviews. Immunology, Journal Year: 2022, Volume and Issue: 22(5), P. 277 - 282

Published: March 18, 2022

Language: Английский

---

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

Science Translational Medicine, Journal Year: 2022, Volume and Issue: 14(634)

Published: Jan. 14, 2022

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that have mutations associated with increased transmission and antibody escape arisen over the course of current pandemic. Although vaccines largely been effective against past variants, number found on Omicron (B.1.1.529) spike protein appear to diminish protection conferred by preexisting immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing several SARS-CoV-2 we evaluated magnitude breadth neutralizing response time in individuals after infection mRNA-vaccinated individuals. We observed boosting increases wild-type (D614), Beta, Delta, variants; however, variant was most resistant neutralization. further vaccinated healthy adults had robust broad responses, whereas responses may reduced pregnant women, underscoring importance learning how maximize mRNA vaccine populations. Findings from this study show substantial heterogeneity vaccination support addition more conserved viral antigens existing vaccines.

Language: Английский

---

mRNA vaccines: The future of prevention of viral infections?

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(2)

Published: Feb. 1, 2023

Abstract Messenger RNA (mRNA) vaccines against COVID‐19 are the first authorized biological preparations developed using this platform. During pandemic, their administration has been proven to be a life‐saving intervention. Here, we review main advantages of mRNA vaccines, identify further technological challenges met during development platform, and provide an update on clinical progress leading vaccine candidates different viruses that include influenza viruses, human immunodeficiency virus 1, respiratory syncytial virus, Nipah Zika cytomegalovirus, Epstein‐Barr virus. The prospects manufacturing in low‐income countries also discussed. ongoing interest research technology likely overcome some existing for (e.g., related storage conditions immunogenicity components lipid nanoparticles) enhance portfolio diseases which classical formulations already authorized. It may open novel pathways protection infections consequences no safe efficient immunization methods currently available.

Language: Английский

---

Neonatal Outcomes After COVID-19 Vaccination in Pregnancy

JAMA, Journal Year: 2024, Volume and Issue: 331(5), P. 396 - 396

Published: Feb. 6, 2024

Importance Better knowledge about neonatal adverse events after COVID-19 vaccination during pregnancy could help address concerns vaccine safety. Objective To evaluate the risks of exposure to pregnancy. Design, Setting, and Participants Population-based cohort study including all infants in Sweden Norway born from June 2021 January 2023. Unique personal identity numbers were used link individual information different national registers. Exposure Administration any mRNA against pregnancy, irrespective previous vaccination, number doses or manufacturer. Main Outcomes Measures conditions with bleeding/thrombosis inflammation/infection; disorders central nervous system; circulatory, respiratory, gastrointestinal problems; mortality. Statistical methods included logistic regression adjusted for characteristics pregnant individuals, additional restricted stratified analyses. Results Of 196 470 newborn (51.3% male, 93.8% at term, 62.5% Sweden), 94 303 (48.0%) exposed Exposed exhibited no increased odds outcomes, they lower nontraumatic intracranial hemorrhage (event rate, 1.7 vs 3.2/1000; ratio [aOR], 0.78 [95% CI, 0.61-0.99]), hypoxic-ischemic encephalopathy (1.8 2.7/1000; aOR, 0.73 0.55-0.96]), mortality (0.9 1.8/1000; 0.68 0.50-0.91]). Subgroup analyses found a similar association between mortality; subgroups delivered by individuals unvaccinated before vaccinated general recommendation was issued, without infection Analyses term infants, singleton births, birth defects yielded results. Stratifying analysis manufacturer did not attenuate low Conclusions Relevance In this large population-based study, vaccines associated their infants.

Language: Английский

---

Delivery technologies for women’s health applications

Nature Reviews Bioengineering, Journal Year: 2023, Volume and Issue: 1(6), P. 408 - 425

Published: March 8, 2023

Language: Английский

---

Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants

Obstetrics and Gynecology Clinics of North America, Journal Year: 2023, Volume and Issue: 50(2), P. 279 - 297

Published: Feb. 21, 2023

Language: Английский

---

A Decrease of Antibodies Against SARS‐CoV‐2 Antigens Does Not Reflect a Decrease of Neutralization Rate: A Prospective Study to Evaluate Kinetic and Dynamic Humoral Immune Response After Vaccination During Pregnancy

American Journal of Reproductive Immunology, Journal Year: 2025, Volume and Issue: 93(2)

Published: Feb. 1, 2025

ABSTRACT Problem Despite being at increased risk for severe COVID‐19, pregnant women were initially excluded from vaccine clinical trials, which limited data regarding effectiveness and protection in this group. Aiming to better understand the immune response vaccination during pregnancy, we compared kinetics titers of neutralizing IgG antibodies generated against SARS‐CoV‐2 with BNT162b2 (Pfizer‐BioNTech) or CoronaVac (Sinovac Biotech) a cohort women. Methods Study We evaluated participants before 30 days after each dose, using multiplex bead assay measure antigens (total spike, spike‐1, spike‐2, receptor binding domain, nucleocapsid) live virus fluorescence reduction neutralization (FRNA) quantify antibodies. Results Our showed that resulted robust humoral response, considerable increase levels first dose sustained boost. In addition, antispike assays presented slight decrease second while rate remained stable. Conclusions Immune demonstrated an important

Language: Английский

---

mRNA-1273 is placenta-permeable and immunogenic in the fetus

Molecular Therapy — Nucleic Acids, Journal Year: 2025, Volume and Issue: 36(1), P. 102489 - 102489

Published: Feb. 17, 2025

COVID-19 mRNA vaccines are generally recognized as safe for gestational administration. However, their transplacental pharmacokinetics remain obscure. In this study, mRNA-1273 intramuscularly given to pregnant mice rapidly circulated in maternal blood and crossed the placenta within 1 h spread fetal circulation. Although spike circulation faded away 4-6 h, it could accumulate tissues, mainly liver get translated into protein. Transplacental proved immunogenic fetuses, postnatally equipped with anti-spike immunoglobulin (Ig)M, paternal allotypic IgG2a, heightened cellular immunity. Gestationally administered, had a dose-dependent effect on its transfer immunogenicity higher doses leading increased passage greater serum titers of endogenous IgM/IgG generated by fetuses. Thus, gestationally vaccination might endow newborns not only passive but also active Our results pose new insights capacity potential advancing our knowledge medicine protect unborns against pathogens perinatal life broaden horizons prenatal molecular therapy.

Language: Английский

---

Systematic review and meta-analysis of neonatal outcomes of COVID-19 vaccination in pregnancy

Pediatric Research, Journal Year: 2023, Volume and Issue: 94(1), P. 34 - 42

Published: Jan. 3, 2023

Abstract Background The safety of coronavirus disease 2019 (COVID-19) vaccines during pregnancy is a particular concern. Here, we addressed the neonatal outcomes after maternal vaccination COVID-19 pregnancy. Methods We systematically searched PubMed, EMBASE, and WHO Database for studies on from inception to 3 July 2022. Main were related preterm, small gestation (SGA), NICU admission, low Apgar score at 5 min (<7), additional such as <34 weeks, birth weight some morbidity all also analyzed. Results A total 15 included. found that was reduction rates Preterm, SGA, Low (<7). In addition, there no evidence higher risk adverse pregnancy, including preterm with weight, very congenital anomalies, so on. Conclusions in pregnant women does not raise significant effects protective effect outcomes. Impact Present study has present could encourage be vaccinated against COVID-19.

Language: Английский

---

Maternal and neonatal outcomes of COVID-19 vaccination during pregnancy, a systematic review and meta-analysis

npj Vaccines, Journal Year: 2023, Volume and Issue: 8(1)

Published: July 15, 2023

Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is associated with increased pregnancy complications. Despite effective vaccination strategies for the general population, evidence on safety and efficacy of disease 2019 (COVID-19) vaccinations in limited due to a lack well-powered studies. The present study compares maternal, neonatal, immunological outcomes between vaccinated pregnant unvaccinated women using systematic review meta-analysis approach. We included 37 studies total 141,107 (36.8% vaccinated) spread across all outcomes. Our indicates higher rate cesarean section 1898 compared 6180 who did not receive (OR = 1.20, CI (1.05, 1.38), P 0.007, I2 45%). Regarding outcomes, risk SARS-CoV-2 infection during or postpartum was significantly reduced 6820 17,010 0.25, 0.13–0.48, < 0.0001, I 61%), as evident from qualitative assessment indicating antibody titers that observed both mothers have recently recovered infection. analysis represents high quality showing COVID-19 effectively raises against SARS-CoV-2. This may confer protection period. In addition being protective SARS-CoV-2, vaccine decreased odds preterm delivery. Furthermore, also be section.

Language: Английский

---